Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Vaxart Stock Quote


Price as of June 24, 2024, 4:00 p.m. ET

Vaxart Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
VXRT -14.95% +11.52% +2.21% -92%
S&P +24.71% +85.21% +13.10% +102%

Vaxart Company Info

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

News & Analysis

The Fool has written over 100 articles on Vaxart.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.